Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Oct 24, 2012 11:29am
296 Views
Post# 20518299

RE: Q3.

RE: Q3.

This Q3 is a tough quarter to predict (July/Aug were likely slow but September probably saw a good uptake in order flow given the release of MAX and connx). Regardless, investors will not be too focussed on the quarter (unless its a disaster). The slate has been wiped clean with the change of management. If the company wants to build investor confidence and show that there is significant earnings potential then this CC is the stage to show it. All eyes are on RH right now to show he has a plan to execute. I'm hoping he won't make the mistake of his predecessor who consistently over promised and under delivered. Now is the time to show that indeed things are different. There are a lot of positives going into 2013, and if execution is proper, it could be a banner year both in terms of topline and earnings. It will be interesting to see their comments.

 

As an aside It's Oct 24th and no press pre-release regarding timing of the CC as of yet. It's possible it'll be later than usual given management is going to want to present some preliminary findings from Farber. If this happens I hope management is smart enough to prelease some numbers to avoid a selloff in the share price (the street often views later than usual conference calls as an omen of bad news).

Bullboard Posts